中文名称  磷酸化抑制基因PTEN抗体说明书 

英文名称  Anti-Phospho-PTEN(Ser380/Thr382/Thr383)

别    名 PTEN(Phospho-Ser380/Thr382/Thr383); PTEN(phospho S380/T382/Thr383); PTEN(Phospho-Ser380/Thr382/Thr383); ITGA 2; MGC11227; MHAM; MMAC 1; MMAC1; Bannayan Zonana; BZS a; Multiple hamartoma (Cowden syndrome); Mutated in Mutiple Advanced Cancers 1; Phosphatase and Tensin Homolog; Phosphatidylinositol 345 trisphosphate 3 phosphatase and dual specificity protein phosphatase PTEN; Phosphatidylinositol 345 trisphosphate 3 phosphatase; Platelet antigen BR; PTEN 1; PTEN1; Tensin homolog; TEP 1; TEP1; VLA 2 Receptor Alpha Subunit.

产品属性：

磷酸化抑制基因PTEN抗体说明书 浓    度  1mg/1ml

规 格  0.1ml/100μg

抗体来源  Rabbit

克隆类型   polyclonal

交叉反应   Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse

产品类型   一抗 磷酸化抗体  

研究领域     细胞生物 免疫学 转录调节因子 激酶和磷酸酶

蛋白分子量  predicted molecular weight: 44kDa 

性    状   Lyophilized or Liquid

免 疫 原  KLH conjugated Synthesised phosphopeptide derived from human PTEN around the phosphorylation site of Ser380/Thr382/Thr383

亚    型  IgG

纯化方法   affinity purified by Protein A

储 存 液   0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide

磷酸化抑制基因PTEN抗体说明书 产品应用   WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500

（石蜡切片需做抗原修复） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存条件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

产品介绍 Potential tumor suppressor. Acts as a phosphoinositide3-phosphatase by regulating PtdIns (3,4,5)P3 levels. Involved in regulation of the AKT1 signaling pathway. The unphosphorylated form cooperates with AIP1 to suppress AKT1 activation.The PTEN/MMAC1 discovers the first to have the suppress of the phosphoric acid enzyme activity cancer gene currently.The gene of PTEN locates the chromosome10q23 area, sending forth sex tumor and a few households cancers with the variety to suffer from the comprehensive disease easilyrelevant.The activity that passes to repress the Akt regulates the cell period, the cell ground rule decease and glues to connect.This text discussed PTEN structure, function and its correlationses, the PTEN is in tumor repress function mechanism.

Function : Tumor suppressor. Acts as a dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins. Also acts as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring from phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3,4-diphosphate, phosphatidylinositol 3-phosphate and inositol 1,3,4,5-tetrakisphosphate with order of substrate preference in vitro PtdIns(3,4,5)P3 > PtdIns(3,4)P2 > PtdIns3P > Ins(1,3,4,5)P4. The lipid phosphatase activity is critical for its tumor suppressor function. Antagonizes the PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival. The unphosphorylated form cooperates with AIP1 to suppress AKT1 activation. Dephosphorylates tyrosine-phosphorylated focal adhesion kinase and inhibits cell migration and integrin-mediated cell spreading and focal adhesion formation. Plays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue. The nuclear monoubiquitinated form possesses greater apoptotic potential, whereas the cytoplasmic nonubiquitinated form induces less tumor suppressive ability.

Subunit : Monomer. The unphosphorylated form interacts with the second PDZ domain of AIP1 and with DLG1 and MAST2 in vitro. Interacts with MAGI2, MAGI3, MAST1 and MAST3, but neither with MAST4 nor with DLG5. Interaction with MAGI2 increases protein stability. Interacts with NEDD4. Interacts with NDFIP1 and NDFIP2; in the presence of NEDD4 or ITCH, this interaction promotes PTEN ubiquitination. Interacts (via C2 domain) with FRK. Interacts with USP7; the interaction is direct. Interacts with ROCK1. Interacts with XIAP/BIRC4.

Subcellular Location : Cytoplasm. Nucleus. Nucleus, PML body. Note=Monoubiquitinated form is nuclear. Nonubiquitinated form is cytoplasmic. Colocalized with PML and USP7 in PML nuclear bodies. XIAP/BIRC4 promotes its nuclear localization.

Post-translational modifications : Constitutively phosphorylated by CK2 under normal conditions. Phosphorylated in vitro by MAST1, MAST2 and MAST3. Phosphorylation results in an inhibited activity towards PIP3. Phosphorylation can both inhibit or promote PDZ-binding. Phosphorylation at Tyr-336 by FRK/PTK5 protects this protein from ubiquitin-mediated degradation probably by inhibiting its binding to NEDD4. Phosphorylation by ROCK1 is essential for its stability and activity. Phosphorylation by PLK3 promotes its stability and prevents its degradation by the proteasome.

Monoubiquitinated; monoubiquitination is increased in presence of retinoic acid. Deubiquitinated by USP7; leading to its nuclear exclusion. Monoubiquitination of one of either Lys-13 and Lys-289 amino acid is sufficient to modulate PTEN compartmentalization. Ubiquitinated by XIAP/BIRC4.

DISEASE : Defects in PTEN are a cause of Cowden disease (CD) [MIM:158350]; also known as Cowden syndrome (CS). CD is an autosomal dominant cancer predisposition syndrome associated with elevated risk for tumors of the breast, thyroid and skin. The predominant phenotype for CD is multiple hamartoma syndrome, in many organ systems including the breast (70% of CD patients), thyroid (40-60%), skin, CNS (40%), gastrointestinal tract. Affected individuals are at an increased risk of both breast and thyroid cancers. Trichilemmomas (benign tumors of the hair follicle infundibulum), and mucocutaneous papillomatosis (99%) are hallmarks of CD.

Defects in PTEN are the cause of Lhermitte-Duclos disease (LDD) [MIM:158350]; also known as cerebelloparenchymal disorder VI. LDD is characterized by dysplastic gangliocytoma of the cerebellum which often results in cerebellar signs and seizures. LDD and CD seem to be the same entity, and are considered as hamartoma-neoplasia syndromes.

Defects in PTEN are a cause of Bannayan-Zonana syndrome (BZS) [MIM:153480]; also known as Ruvalcaba-Myhre-Smith syndrome (RMSS) or Bannayan-Riley-Ruvalcaba syndrome (BRRS). In BZS there seems not to be an increased risk of malignancy. It has a partial clinical overlap with CD. BZS is characterized by the classic triad of macrocephaly, lipomatosis and pigmented macules of the gland penis.

Defects in PTEN are a cause of head and neck squamous cell carcinomas (HNSCC) [MIM:275355]; also known as squamous cell carcinoma of the head and neck.

Defects in PTEN are a cause of susceptibility to endometrial cancer (ENDMC) [MIM:608089].

Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.

Defects in PTEN are a cause of susceptibility to glioma type 2 (GLM2) [MIM:613028]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas.

[DISEASE] Defects in PTEN are a cause of VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]. VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects.

Defects in PTEN may be a cause of susceptibility to prostate cancer (PC) [MIM:176807]. It is a malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma.

Defects in PTEN are a cause of macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]. Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD).

Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.

Similarity : Contains 1 C2 tensin-type domain.

Contains 1 phosphatase tensin-type domain.

Database links : UniProtKB/Swiss-Prot: P60484.1

PTEN是一种抑制基因，在维持细胞的增殖、分化和凋亡平衡起重要作用，该基因在许多常表现为突变或杂合性丢失，NMAC1主要用于、乳腺、、非何杰金氏各种的研究.

实验流程：

全、新、优、品、好四大特点：

磷酸化抑制基因PTEN抗体说明书 全：公司提供上万种产品，涵盖了生物试剂，elisa试剂盒，标准品，培养基，原装耗材，抗体、培养基、ATCC细胞等，基本上各种科研所需产品在我司都能找到。

新：产品更新速度较快，基本上每周都有新产品出现。

优：产品质量好，投诉比较少。

好：我公司具有优质的技术团队，产品一旦售出，实验过程中遇到困难可提供在线技术咨询。使您使用产品时没有任何的后顾之忧。

技术外包服务:

★磷酸化抑制基因PTEN抗体说明书 分子生物学：质粒抽提、PCR、Q-PCR、RT-PCR、分子生物学：基因合成、引物合成、基因测序、载体构建等

★蛋白工程：原核、哺乳动物蛋白表达系统等

★病毒包装：腺病毒、慢病毒等

★抗体工程：磁珠分选、病理染色、WB、ELISA、IP、IF、IHC、FACS、Confocal等等

★细胞工程：细胞表型分析(凋亡、增殖、周期、迁移、侵袭、修复、克隆形成)、细胞培养、细胞膜制备、稳定细胞株构建、细胞RNAi技术等等。

正在热销的相关产品：

Anti-CD20/MS4A1/PE 荧光素PE标记CD20抗体IgGMulti-class antibodies规格： 0.2ml

Anti-Hpt/HP /FITC 荧光素标记结合珠蛋白/触珠蛋白抗体IgGMulti-class antibodies规格： 0.2ml

Rhesus antibody Rh Cdc25B 细胞分裂周期蛋白25B抗体 规格 0.1ml

ADAMTS-7(a disintegrin-like and metalloprotease-7 ) 新型金属基质蛋白酶(抗原) 0.5mg

IFIT1B 英文名称： 干扰素诱导的三角形四肽重复蛋白1B抗体 0.2ml

Rhesus antibody Rh TDP-43 Tar DNA 结合蛋白43抗体 规格 0.1ml

Anti-Hpt/HP /FITC 荧光素标记结合珠蛋白/触珠蛋白抗体IgGMulti-class antibodies规格： 0.2ml

anti-Integrin alpha E2 /FITC 荧光素标记整合素alpha E2 抗体IgGMulti-class antibodies规格： 0.2ml

Anti-Phospho-S6 Ribosomal Protein (Ser240/244) /FITC 荧光素标记磷酸化S6核糖体蛋白抗体IgGMulti-class antibodies规格： 0.2ml

Rhesus antibody Rh ANKRD26 锚蛋白重复结构域蛋白26抗体 规格 0.2ml

Rabbit Anti-Monkey IgM/Gold 胶体金标记的兔抗猴IgM 0.5ml

GCDGP15 英文名称： 囊性组织液体蛋白15抗体 0.1ml

Rhesus antibody Rh Rabbit Anti-human IgG F(ab')2/Cy3 Cy3标记的兔抗人IgG F(ab')2 规格 0.1ml

Anti-Phospho-S6 Ribosomal Protein (Ser240/244) /FITC 荧光素标记磷酸化S6核糖体蛋白抗体IgGMulti-class antibodies规格： 0.2ml

HSP-27 ELISA Kit 大鼠热休克蛋白27Multi-class antibodies规格： 48T

Anti-TRAF2 坏死因子受体相关因子2抗体Multi-class antibodies规格： 0.2ml

Rhesus antibody Rh GLB1L3 β半乳糖苷酶1样蛋白3抗体 规格 0.2ml

GP- II b III a/CD41+CD61 ELISA Kit 大鼠血小板膜糖蛋白ⅡbⅢa 96T

phospho-NIPA(Ser354) 英文名称： 磷酸化间变性激酶核相互作用伴侣蛋白抗体 0.1ml

Beta-arrestin 1 英文名称： β-抑制蛋白1抗体 0.2ml

Anti-TRAF2 坏死因子受体相关因子2抗体Multi-class antibodies规格： 0.2ml

CL-0092HBZY-1(大鼠肾小球系膜细胞)5×106cells/瓶×2

CLEC14A Others Rat 大鼠 CLEC14A / EGFR-5 人细胞裂解液 (阳性对照)

人海马趾神经细胞裂解物HN-h L

Caov-3细胞，人细胞 大鼠胰岛素细胞,INS-1细胞 神经元细胞Many types of cells包装：5 ×105次方(1ml)

Chang liver (CCL13) (人张氏肝细胞) 5×106cells/瓶×2

SkMC Pellet 人骨骼肌细胞团块 > 1 mio.cells 人基质细胞cDNAHHGMC cDNA

CL-0090Hacat(人永生化角质形成细胞)5×106cells/瓶×2

MBL2 Others Human 人 MBL2 / MBL / COLEC1 CHO细胞裂解液 (阳性对照)

人神经细胞裂解物HNL

牛肾细胞;MDBK 人咽鳞癌细胞，FaDu细胞 Nb2-11细胞，小鼠细胞

EB病毒转化的人B淋巴细胞;KM932

THSD1 Others Mouse 小鼠 THSD1 / TMTSP 人细胞裂解液 (阳性对照)

磷酸化抑制基因PTEN抗体说明书 SDC4 Others Mouse 小鼠 Syndecan-4 / SDC4 人细胞裂解液 (阳性对照)

人胚;MRC-5

HCCC-9810 人胆管细胞型细胞

293 Cells, low passage人胚肾细胞 293 Cells, low and passage in human embryo kidney cell 人胚肾细胞

LTA Protein Human 重组人 TNF-beta / TNFSF1 / Lymphotoxin alpha 蛋白

人脐带动脉内皮细胞 (HUAEC)( 5×105 ) A549, 人细胞系 Human